View Older Stories View More Recent Stories
-
Baird: 'Acadia shares should come out relatively unscathed after the dust settles'
-
ACAD failure eliminates a competitive threat to Soleno Therapeutics (SLNO) - Oppenheimer
-
BMO Capital: 'expect ACAD shares to decline'
-
Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
-
Stifel on Soleno Therapeutics Inc. (SLNO): 'we remain bullish and believe Vykat is well-positioned for significant/sustained growth'
-
Stifel Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) to Resume Trading at 7:30 a.m.
-
Acadia Pharma (ACAD) Halted, News Pending
-
UBS Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
ACADIA publishes real-world data on DAYBUE for Rett syndrome treatment
-
Acadia Pharmaceuticals (ACAD) PT Raised to $39 at TD Cowen
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at Mizuho
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Stifel
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Mizuho
-
Acadia Pharmaceuticals (ACAD) PT Raised to $38 at Citizens JMP
-
Acadia Pharma (ACAD) Tops Q2 EPS by 2c
-
ACADIA names Scott Cenci as chief information and data officer
-
Acadia Pharmaceuticals (ACAD) PT Raised to $32 at UBS
-
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
RBC Capital Reiterates Outperform on Acadia Pharmaceuticals (ACAD) Following R&D Day
-
BMO Capital Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
-
Acadia Pharmaceuticals (ACAD) PT Raised to $38 at RBC Capital
-
Cantor Fitzgerald Reiterates Overweight Rating on Acadia Pharmaceuticals (ACAD)
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent
-
Acadia Pharmaceuticals (ACAD) PT Raised to $30 at JPMorgan
-
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at BofA Securities
-
Acadia Pharma (ACAD) Appoints Allyson McMillan-Youngblood as SVP, Rare Disease Franchise
-
Deutsche Bank Upgrades Acadia Pharmaceuticals (ACAD) to Buy
-
RBC Capital on Acadia Pharmaceuticals (ACAD): 'PWS Readout Asymmetrically Skewed to Upside'
-
BMO Capital on Acadia Pharmaceuticals (ACAD): 'IP Protection Pushes Target to $28'
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Morgan Stanley
-
Acadia Pharmaceuticals (ACAD) PT Raised to $32 at H.C. Wainwright
-
Acadia Pharma (ACAD) announces that Delaware Court has ruled in its favor for NUPLAZID litigation
-
Acadia Pharmaceuticals (ACAD) PT Raised to $19 at Oppenheimer
-
Acadia Pharmaceuticals (ACAD) IP Decision 'Removes a Key Overhang' - BMO Capital
-
Acadia Pharma (ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders
-
Stifel Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Acadia Pharma (ACAD) reports inducement grants
-
Cantor Biotech industry report, buying value in RevGens
